Enhabit (EHAB) Competitors $7.28 -0.35 (-4.53%) Closing price 03:59 PM EasternExtended Trading$7.28 +0.01 (+0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EHAB vs. AHCO, TDOC, GRAL, PNTG, AVAH, CDNA, FLGT, CSTL, FTRE, and LFMDShould you be buying Enhabit stock or one of its competitors? The main competitors of Enhabit include AdaptHealth (AHCO), Teladoc Health (TDOC), GRAIL (GRAL), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), CareDx (CDNA), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Fortrea (FTRE), and LifeMD (LFMD). These companies are all part of the "healthcare" industry. Enhabit vs. Its Competitors AdaptHealth Teladoc Health GRAIL The Pennant Group Aveanna Healthcare CareDx Fulgent Genetics Castle Biosciences Fortrea LifeMD AdaptHealth (NASDAQ:AHCO) and Enhabit (NYSE:EHAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Which has preferable valuation and earnings, AHCO or EHAB? AdaptHealth has higher revenue and earnings than Enhabit. Enhabit is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptHealth$3.26B0.39$90.42M$0.5417.28Enhabit$1.04B0.35-$156.20M-$2.67-2.72 Do analysts rate AHCO or EHAB? AdaptHealth presently has a consensus target price of $13.40, indicating a potential upside of 43.62%. Enhabit has a consensus target price of $8.67, indicating a potential upside of 19.13%. Given AdaptHealth's stronger consensus rating and higher probable upside, research analysts plainly believe AdaptHealth is more favorable than Enhabit.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AdaptHealth 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Enhabit 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer AHCO or EHAB? In the previous week, AdaptHealth had 5 more articles in the media than Enhabit. MarketBeat recorded 15 mentions for AdaptHealth and 10 mentions for Enhabit. Enhabit's average media sentiment score of 0.29 beat AdaptHealth's score of 0.17 indicating that Enhabit is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AdaptHealth 3 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enhabit 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, AHCO or EHAB? AdaptHealth has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Enhabit has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Is AHCO or EHAB more profitable? AdaptHealth has a net margin of 2.49% compared to Enhabit's net margin of -12.84%. AdaptHealth's return on equity of 5.01% beat Enhabit's return on equity.Company Net Margins Return on Equity Return on Assets AdaptHealth2.49% 5.01% 1.77% Enhabit -12.84%2.72%1.25% Do insiders & institutionals believe in AHCO or EHAB? 82.7% of AdaptHealth shares are held by institutional investors. 1.6% of AdaptHealth shares are held by company insiders. Comparatively, 3.4% of Enhabit shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryAdaptHealth beats Enhabit on 13 of the 16 factors compared between the two stocks. Get Enhabit News Delivered to You Automatically Sign up to receive the latest news and ratings for EHAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EHAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EHAB vs. The Competition Export to ExcelMetricEnhabitMedical Services IndustryMedical SectorNYSE ExchangeMarket Cap$368.38M$7.33B$5.45B$20.59BDividend YieldN/A2.81%4.60%3.65%P/E Ratio-2.7267.8329.8627.94Price / Sales0.3526.59378.0888.65Price / Cash1.8625.9324.8417.60Price / Book0.677.908.604.60Net Income-$156.20M$243.10M$3.26B$994.05M7 Day Performance9.65%-0.10%0.53%0.27%1 Month Performance3.19%-2.25%1.38%-1.22%1 Year Performance-14.01%17.69%36.55%14.26% Enhabit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EHABEnhabit1.9416 of 5 stars$7.28-4.5%$8.67+19.1%-10.3%$368.38M$1.04B-2.7210,700Earnings ReportAnalyst ForecastAHCOAdaptHealth3.9115 of 5 stars$9.51+4.4%$13.40+40.8%-2.4%$1.23B$3.26B15.9410,500Analyst UpgradeTDOCTeladoc Health2.8277 of 5 stars$6.91-0.9%$9.76+41.4%-2.5%$1.22B$2.57B-5.785,500GRALGRAIL1.2168 of 5 stars$32.77-1.4%$31.50-3.9%+103.1%$1.20B$125.60M-0.551,360Upcoming EarningsPNTGThe Pennant Group3.3996 of 5 stars$22.44+1.7%$33.80+50.6%-14.2%$760.73M$695.24M29.167,000News CoverageAnalyst UpgradeAVAHAveanna Healthcare0.7035 of 5 stars$3.87+3.3%$5.25+35.8%+30.4%$738.42M$2.02B189.2533,500News CoverageAnalyst UpgradeGap UpCDNACareDx4.0841 of 5 stars$12.26+0.3%$29.33+139.3%-55.7%$699.45M$333.79M10.92740Earnings ReportAnalyst ForecastFLGTFulgent Genetics4.1577 of 5 stars$19.67+7.1%$25.33+28.8%-14.9%$606.12M$283.47M-12.001,313CSTLCastle Biosciences3.2467 of 5 stars$19.53+27.4%$37.00+89.5%-27.8%$590.88M$332.07M-107.72540Earnings ReportAnalyst UpgradeFTREFortrea3.8932 of 5 stars$6.20-3.5%$13.73+121.6%-73.8%$574.77M$2.70B-0.7215,500Earnings ReportAnalyst ForecastAnalyst RevisionLFMDLifeMD2.5019 of 5 stars$12.10-2.0%$13.86+14.5%+25.6%$561.04M$212.45M-36.30230Analyst RevisionGap Up Related Companies and Tools Related Companies AHCO Competitors TDOC Competitors GRAL Competitors PNTG Competitors AVAH Competitors CDNA Competitors FLGT Competitors CSTL Competitors FTRE Competitors LFMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:EHAB) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enhabit, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enhabit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access